戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nosine receptors instead of administering an adenosine receptor agonist.
2 lymeric (PEG-b-PLA) nanoparticles for use as adenosine receptor agonists.
3 eukin-1 (IL-1) in the presence or absence of adenosine receptor agonists.
4                                    The A(2A) adenosine receptor agonist, 2-p-(2-carboxyethyl)phenylam
5  mobilization stimulated by the nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos
6       These responses were reproduced by the adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos
7                             The nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos
8 ily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
9 es supplemented with adenosine, but not with adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
10 lls were stimulated by focal ejection of the adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
11                             The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
12                             The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
13         Administration of the broad-spectrum adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
14                             The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin
15      Treatment of mice with the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadensoin
16 t evidence that a small molecule, such as an adenosine receptor agonist, accelerates wound healing in
17                                              Adenosine receptor agonists and a KATP channel opener we
18           Characterization of the effects of adenosine receptor agonists and antagonists has led to n
19           In the present study, we delivered adenosine receptor agonists and antagonists into the lat
20                      Studies using selective adenosine receptor agonists and antagonists suggested th
21 ignificantly altered by dialysis delivery of adenosine receptor agonists and antagonists to the prefr
22 n acute and long-term treatment studies with adenosine receptor agonists and antagonists.
23  variety of well-characterized adenosine and adenosine receptor agonists and antagonists.
24 n unexpected synergistic interaction between adenosine receptor agonists and phosphodiesterase (PDE)
25 diators of preconditioning, e.g., adenosine, adenosine receptor agonists, and adenosine triphosphate-
26                       We have used selective adenosine receptor agonists, antagonists, and PDE inhibi
27 PS) in the presence or absence of adenosine, adenosine receptor agonists/antagonists, or CBD.
28                                 Certain A(3) adenosine receptor agonists are being developed for the
29                      However, efforts to use adenosine receptor agonists are plagued by dose-limiting
30 ns, VEGF expression is slightly increased by adenosine receptor agonists but adenosine A(2) or A(1) r
31                  These data demonstrate that adenosine receptor agonists can induce an acute rise in
32 red the effect of topical application of the adenosine receptor agonist CGS-21680 (2-p-[2-carboxyethy
33  epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladeno
34                               While the A(1) adenosine receptor agonist CPA and the A(2A) receptor an
35               The lipid-soluble, Al-specific adenosine receptor agonist cyclopentyladenosine, dose-de
36                                   Adenosine, adenosine-receptor agonists, dibutyryl cAMP, forskolin,
37 loyed to study the functional consequence of adenosine receptor agonists directly on neuronal membran
38 tive chronotropic responses to muscarinic or adenosine receptor agonists do not require activation of
39 hat infusion of either adenosine (ADO) or an adenosine receptor agonist during reperfusion after hypo
40 osine (EC50: 0.5 microM) and NECA (universal adenosine receptor agonist; EC50 0.1 microM) stimulated
41 h clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or o
42 ss-linking, direct influx of calcium, and/or adenosine receptor agonist exposure.
43 R such as forskolin, beta2-adrenergic or A2B-adenosine receptor agonists failed to activate rescued d
44                                              Adenosine receptor agonists have cardioprotective, cereb
45            In the heart, these effects of A1 adenosine receptor agonists have not been reported.
46 demonstrate that in conscious rabbits the A3 adenosine receptor agonist IB-MECA confers a powerful pr
47                                    Selective adenosine receptor agonists implicated the A2b adenosine
48 g protection, and they implicate inhaled A2B adenosine receptor agonists in ALI treatment.
49 onamide (IB-MECA), a potent and selective A3 adenosine receptor agonist, in models of myocardial stun
50 sine receptors by adenosine and selective A1 adenosine receptor agonists mimics the protective effect
51  of benzyloxy and phenoxy derivatives of the adenosine receptor agonists N(6)-cyclopentyl adenosine (
52  was equivalent to that obtained with the A1-adenosine receptor agonist N6-cyclopentyladenosine (1.56
53  the presence or absence of the nonselective adenosine receptor agonist NECA (5'-N-ethylcarboxamidoad
54    The effect of inosine was mimicked by the adenosine receptor agonist NECA and the A2B receptor ago
55                           The selective A(2)-adenosine receptor agonist NECA but not the A(1)-adenosi
56                            The non-selective adenosine receptor agonist NECA effectively inhibited IA
57                                          The adenosine receptor agonist NECA inhibited interferon-gam
58 sed to assess the impact of adenosine and/or adenosine receptor agonists on proliferation, apoptosis,
59 GABA in the inhibitory actions of A1 and A2a adenosine receptor agonists on rat cerebral cortical neu
60                                              Adenosine receptor agonists or antagonists were administ
61 secondary to hypoxia was reversed in part by adenosine receptor agonists or reconstitution with solub
62 eta-EP was elevated following treatment with adenosine receptor agonist phenyl-isopropyl adenosine (P
63 (2-phenylisopropyl) adenosine (PIA), an A(1)-adenosine receptor agonist; preconditioned hearts pretre
64                                              Adenosine receptor agonists produce a wide variety of th
65                                     Although adenosine receptor agonists produce similar effects, AKI
66 orted that prior treatment with selective A1 adenosine receptor agonists results in a rapid uncouplin
67 f ischemia of the heart with adenosine or A1 adenosine receptor agonists results in uncoupling of A1
68             Although the order of potency of adenosine receptor agonists suggested the involvement of
69                                   An A2-type adenosine receptor agonist suppresses these effects of I
70  we tested the P-gp interaction of some A(3) adenosine receptor agonists that are being developed for
71 Thus, small, highly permeable drugs (such as adenosine receptor agonists) that transactivate TrkB rec
72 rated that administration of a selective A2A adenosine receptor agonist to CD73-deficient mice result
73 te to inhibit the binding of [3H]CCPA, an A1-adenosine receptor agonist, to brain membranes.
74  reduce the binding of [3H]CGS 21680, an A2a-adenosine receptor agonist, to striatal membranes.
75                             Correspondingly, adenosine receptor agonist treatment also limited HDM-dr
76                             Additionally, an adenosine receptor agonist was tested to study the mecha
77                 Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerabili
78         Tecadenoson is a potent selective A1-adenosine receptor agonist with a dose-dependent negativ
79                     The potent A2A-selective adenosine receptor agonist WRC-0470 is a short-acting co
80      Infusions of a potent and selective A2A adenosine receptor agonist, WRC-0470 (0.1 to 3 microgram